The FDA issued a complete response letter for glofitamab-gxbm plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), citing insufficient STARGLO trial ...
Please provide your email address to receive an email when new articles are posted on . The FDA denied glofitamab as second-line DLBCL therapy, noting insufficient evidence for U.S. population.
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at ...
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Glofitamab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides ...
8d
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...
(RTTNews) - Genentech, a member of Swiss drug major Roche Group (RHHBY), announced Friday that the U.S. Food and Drug Administration has accepted its Biologics License Application or BLA and granted ...
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory disease This Columvi regimen offers an ...
The evaluation committee considered evidence submitted by Roche, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The FDA has granted accelerated approval to ...
Data from a phase III trial confirmed the benefit of glofitamab (Columvi) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with the bispecific antibody improving overall survival (OS) ...
The glofitamab population was well matched to the baseline characteristics of the ZUMA‑1 population. But it was likely that the ZUMA‑1 population excluded the more unwell people, and it was not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results